Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients

Published:2022-04-27 Issue:5 Volume:18 Page:495-512
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Zanetta Chiara¹²,Rocca Maria A.¹³⁴,Filippi Massimo¹²³⁴⁵

Affiliation:

1. Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

2. Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

3. Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

4. Vita-Salute San Raffaele University, Milan, Italy

5. Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2022.2064845

Reference97 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

2. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

3. [6th March 2022, 17:21]. Available from: https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6.

4. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta‐analysis

5. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flu-like syndrome due to interferon-beta injections does not increase anxiety, depression, and lost working days in multiple sclerosis patients during the Sars-CoV-2 pandemic;Clinical Neurology and Neurosurgery;2023-09

2. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab;Frontiers in Immunology;2022-12-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3